Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment;Konzeption und Verlauf von acht Schwangerschaften bei fünf Patientinnen unter TNF-α-Blockade mit Etanercept

Zeitschrift fur Rheumatologie

Volumn 69, Issue 10, 2010, Pages 903-909

  Rump, J A ^a   Schonborn H ^a  

^a Praxis für Rheumatologie and Klinische Immunologie ^*  (Germany)

Author keywords

Ankylosing spondylitis; Deformities; Pregnancy; Rheumatoid arthritis; TNF inhibitors

Indexed keywords

ETANERCEPT;

ANKYLOSING SPONDYLITIS; ARTICLE; CASE STUDY; CLINICAL ARTICLE; CONCEPTION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; GESTATIONAL AGE; HIRSCHSPRUNG DISEASE; HUMAN; OUTCOME ASSESSMENT; PREGNANCY; RHEUMATOID ARTHRITIS; SPONTANEOUS ABORTION; TREATMENT WITHDRAWAL;

ABORTION, SPONTANEOUS; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, RHEUMATOID; FEMALE; HIRSCHSPRUNG DISEASE; HUMANS; IMMUNOGLOBULIN G; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650170917     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-010-0652-y     Document Type: Article

References (24)

1. Strangfeld A (2008) RABBIT Studienergebnisse: Schwangerschaft und Biologika; Web-Site DGRh: http://www.dgrh.de/rabbitschanger.html
2. Bingham CO 3rd (2008) Emerging therapeutics for rheumatoid arthritis. Bull NYU Hosp Jt Dis 66:210-215
3. Carter JD, Ladhani A, Ricca LR et al (2009) A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 36:635-641
4. Carter JD, Valeriano J, Vasey FB (2006) Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. J Rheumatol 33:1014-1017
5. Chakravarty EF, Sanchez-Yamamoto D, Bush TM (2003) The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 30:241-246 (Pubitemid 36152584)
6. Chambers C, Johnson D, Lyons-Jones K (2005) Safety of anti-TNF-alpha-medications in pregnancy. J Am Acad Dermatol: abstract P2796
7. Cush JJ (2005) Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis 64:iv18-iv23 (Pubitemid 41532011)
8. Garcia-Gonzalez A, Joven B, Ruiz T et al (2006) Pregnancy in women receiving anti TNF-alpha therapy: experience in Spain. Ann Rheum Dis 65:317 (abstract)
9. Giroir BP, Peppel K, Silva M, Beutler B (1992) The biosynthesis of tumor necrosis factor during pregnancy: studies with a CAT reporter transgene and TNF inhibitors. Eur Cytokine Netw 3:533-538
10. Haricharan RN, Georgeson KE (2008) Hirschsprung disease. Semin Pediatr Surg 17:266-275
11. Hyrich K, Watson K, Dixon W et al (2006) Pregnancy experience in women with rheumatic diseases exposed to biologic agents: results from the BSR biologic register. Ann Rheum Dis 65:321 (abstract)
12. Hyrich KL, Symmons DP, Watson KD, Silman AJ (2006) Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum 54:2701-2702 (Pubitemid 44205032)
13. Koren G, Inoue M (2009) Do tumor necrosis factor inhibitors cause malformations in humans? J Rheumatol 36:465-466
14. Kuprash DV, Alimzhanov MB, Tumanov AV et al (1999) TNF and lymphotoxin beta cooperate in the maintenance of secondary lymphoid tissue microarchitecture but not in the development of lymph nodes. J Immunol 163:6575-6580
15. Murashima A, Watanabe N, Ozawa N et al (2009) Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infants serum. Ann Rheum Dis 68:1793-1794
16. Ostensen M, Eigenmann GO (2004) Etanercept in breast milk. J Rheumatol 31:1017-1018
17. Ostensen M, Lockshin M, Doria A et al (2008) Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 47:iii28-iii31
18. Sills ES, Perloe M, Tucker MJ et al (2001) Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anti-cytokine treatment for rheumatoid arthritis. Am J Reprod Immunol 46:366-368 (Pubitemid 33034820)
19. Man YA de, Hazes JM, Geijn FE van de et al (2007) Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. Arthritis Rheum 57:716-722 (Pubitemid 46932075)
20. Strangfeld A, Listing J, Rau R et al (2007) Pregnancy outcome after exposure to biologics: results from the German biologics register RABBIT. ACR No. 730 (abstract)
21. Vinet E, Pineau C, Gordon C et al (2009) Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum 61:587-592
22. Wallace DJ (2003) The use of etanercept and other tumor necrosis factor-alpha blockers in infertility: its time to get serious. J Rheumatol 30:1897-1899 (Pubitemid 37075532)
23. Krüger K, Gromnica-Ihle E (2008) Pharmakotherapie in der Schwangerschaft und Stillzeit. Kommission Pharmakotherapie der DGRh
24. Man YA de, Dolhain RJ, Geijn FE van de et al (2008) Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 59:1241-1248